Showing 11-20 of 25 results for "".
- AAD Awards 26 Shade Structure Grants to Protect America's Youthhttps://practicaldermatology.com/news/aad-awards-26-shade-structure-grants-to-protect-americas-youth/2457796/The American Academy of Dermatology (AAD) has awarded Shade Structure grants to 26 schools and nonprofit organizations across the country. The AAD awarded its 2018 AAD Shade Structure grants to the following organizations: Alabama Buhl Elementary School, Buhl, Sponsored by Kare…
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename Esk…
- Aclaris Therapeutics Receives US Patent Covering a JAK Inhibitor for Treating Hair Loss Disordershttps://practicaldermatology.com/news/aclaris-therapeutics-receives-us-patent-covering-a-jak-inhibitor-for-treating-hair-loss-disorders/2457840/The United States Patent and Trademark Office (USPTO) issued US Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders. This newly allowed patent is owned by The Trustees of Columbia Univers…
- South Beach Symposium to Kick Off March 1https://practicaldermatology.com/news/south-beach-symposium-to-kick-off-march-1/2457895/Now celebrating its 16th year, the 2018 South Beach Symposium (SBS) will feature live demonstration workshops of minimally invasive aesthetic treatments with injectables and devices providing attendees with new skills and techniques that can easily be adapted to their current practice. Under the di…
- SK Breakthrough: FDA Approves Eskata (hydrogen peroxide) Topical Solution from Aclarishttps://practicaldermatology.com/news/sk-breakthrough-fda-approves-eskata-hydrogen-peroxide-topical-solution-from-aclaris/2457950/The FDA has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) from Aclaris Therapeutics, Inc. for the treatment of seborrheic keratoses (SKs). SKs are non-cancerous skin growths that affect more than 83 million American adults. They may frequently appear in highly visible areas such …
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of scarring or hypopigmentation. The new findings appear in the journal Dermatologi…
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentralized…
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription me…
- Brickell Biotech Achieves Positive Phase 2b Results for BBI-4000 for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-achieves-postive-phase-2b-results-for-bbi-4000-for-hyperhidrosis/2458772/Brickell Biotech, Inc. shared the results of its Phase 2b study of BBI-4000 (sofpironium bromide) for the topical treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The multicenter, randomized, double blind, vehicle-controlled Phase 2b study was designed to evaluate the sa…
- Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operationshttps://practicaldermatology.com/news/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operations/2458784/Aclaris Therapeutics, Inc. has appointed Brett Fair as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 years of pharmaceutical commercialization and business development experience to Aclaris. He has substantial experience with global pharmaceutical companies and has …